Novo Nordisk has acquired Akero Therapeutics for $4.7 billion, enhancing its liver and metabolic disease portfolio and expanding its U.S. R&D capabilities.

Information on the Target

Novo Nordisk has completed a significant acquisition of Akero Therapeutics, valued at $4.7 billion. Following this transaction, Akero Therapeutics will become a wholly owned subsidiary and will be delisted from Nasdaq.

The acquisition also includes an additional contingent value right (CVR) payment of $0.5 billion based on the FDA's approval of EFX for MASH-related cirrhosis. This strategic move is intended to enhance Novo Nordisk’s portfolio in liver and metabolic diseases, while also aiming to expand its research and development operations within the United States.

Industry Overview in the United States

The healthcare sector in the United States is marked by rapid advancements and a growing emphasis on addressing chronic diseases, particularly metab